In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series A-1 brings in $6.8mm for Cerecor

Executive Summary

Cerecor Inc. (neurology and respiratory therapeutics) raised $6.8mm through its Series A-1 preferred stock financing to 146 undisclosed investors. The company will use the funds to complete the technology transfer of CERC301 (a Phase II-ready selective NR2B antagonist for depression) and the COMT platform from Merck & Co. Inc. Cerecor has raised $30mm since its 2011 inception.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies